71220Jiujiang University, China.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338211072989. doi: 10.1177/15330338211072989.
tRNA-derived small non-coding RNAs (tsncRNAs) are one of mysterious small non-coding RNAs. Dysregulated tsncRNAs can led to all kinds of cancers. Recently, tsncRNAs were postulated to be potentially useful biomarkers for tumor diagnosis and prognosis. However, there were no systematic reviews of prognostic and diagnostic tsncRNAs in neoplasms. The study aimed to decipher the relationships between tsncRNAs expression, diagnostic and prognostic outcome in tumors. This study systematically searched Google Scholar, MEDLINE, Scopus, PubMed, Embase, ScienceDirect, Ovid-Medline, Chinese National Knowledge Infrastructure, WanFang and SinoMed databases for relevant articles published before September 21, 2020. The study is registered in PROSPERO (CRD42020213863). Fourteen relevant studies were included in the meta-analysis: 12 on diagnosis and 5 on prognosis. The pooled add ratio, 95% confidence intervals (Cl) and hazard ratios (HR) of the studies were used to investigate the clinical parameters and overall survival (OS) of cancer patients. The area under the curve (AUC), sensitivity, and specificity was 0.79, 72%, and 73% in tumors, respectively. Though abnormally expressed tsncRNAs were associated with poor and unfavorable impacts on the OS time of cancer patients, the oncogenic tsncRNA may be a favorable impact on overall survival (OS: HR = 0.67, 95% Cl: 0.48-0.94, = 0.02), and tumor-suppressor tsncRNA might have an unfavorable impact on overall survival (OS: HR = 1.41, 95% Cl: 0.84-2.37, = 0.19). These results strongly suggested that tsncRNAs were potential novel prognostic and diagnostic indicators in tumors.
tRNA 衍生的小非编码 RNA(tsncRNA)是神秘的小非编码 RNA 之一。失调的 tsncRNA 可导致各种癌症。最近,tsncRNA 被认为是肿瘤诊断和预后的潜在有用生物标志物。然而,目前还没有关于肿瘤中预后和诊断 tsncRNA 的系统评价。本研究旨在阐明 tsncRNA 表达与肿瘤诊断和预后结果之间的关系。本研究系统地检索了 Google Scholar、MEDLINE、Scopus、PubMed、Embase、ScienceDirect、Ovid-Medline、中国国家知识基础设施、万方和中国生物医学文献数据库,以获取截至 2020 年 9 月 21 日发表的相关文章。本研究已在 PROSPERO(CRD42020213863)中注册。有 14 项相关研究纳入荟萃分析:12 项用于诊断,5 项用于预后。使用研究的汇总加比、95%置信区间(Cl)和风险比(HR)来研究癌症患者的临床参数和总生存期(OS)。曲线下面积(AUC)、敏感性和特异性分别为 0.79、72%和 73%。尽管异常表达的 tsncRNA 与癌症患者 OS 时间的不良影响相关,但致癌 tsncRNA 可能对总生存期(OS:HR=0.67,95%Cl:0.48-0.94,=0.02)有有利影响,而肿瘤抑制性 tsncRNA 可能对总生存期(OS:HR=1.41,95%Cl:0.84-2.37,=0.19)有不利影响。这些结果强烈表明,tsncRNA 是肿瘤中潜在的新型预后和诊断指标。